fluticason cipla
niromed, uab - flutikazonas - suslėgtoji įkvepiamoji suspensija - 125 µg/dozėje - fluticasone
bosentan cipla
lex ano, uab - bozentanas - plėvele dengtos tabletės - 125 mg - bosentan
fluticason cipla
nenurodyta - flutikazonas - suslėgtoji įkvepiamoji suspensija - 125 µg/dozėje - fluticasone
belargan
sia ingen pharma - desloratadinas - plėvele dengtos tabletės - 5 mg - desloratadine
esepa
sia ingen pharma - ezomeprazolas - skrandyje neirios tabletės - 20 mg; 40 mg - esomeprazole
xelcip
viasana, uab - kapecitabinas - plėvele dengtos tabletės - 150 mg - capecitabine
xelcip
viasana, uab - kapecitabinas - plėvele dengtos tabletės - 500 mg - capecitabine
dutasteride/tamsulosin exeltis
exeltis baltics, uab - dutasteridas/tamsulozino hidrochloridas - kietosios kapsulės - 0,5 mg/0,4 mg - tamsulosin and dutasteride
imfinzi
astrazeneca ab - durvalumab - karcinoma, nesmulkiųjų ląstelių skausmas - antinavikiniai vaistai - non-small cell lung cancer (nsclc)imfinzi as monotherapy is indicated for the treatment of locally advanced, unresectable non small cell lung cancer (nsclc) in adults whose tumours express pd-l1 on ≥ 1% of tumour cells and whose disease has not progressed following platinum based chemoradiation therapy (see section 5. imfinzi in combination with tremelimumab and platinum-based chemotherapy is indicated for the first-line treatment of adults with metastatic nsclc with no sensitising egfr mutations or alk positive mutations. small cell lung cancer (sclc)imfinzi in combination with etoposide and either carboplatin or cisplatin is indicated for the first-line treatment of adults with extensive-stage small cell lung cancer (es-sclc). biliary tract cancer (btc)imfinzi in combination with gemcitabine and cisplatin is indicated for the first line treatment of adults with unresectable or metastatic biliary tract cancer (btc). hepatocellular carcinoma (hcc)imfinzi in combination with tremelimumab is indicated for the first line treatment of adults with advanced or unresectable hepatocellular carcinoma (hcc).
imjudo
astrazeneca ab - tremelimumab - carcinoma, hepatocellular - antinavikiniai vaistai - imjudo in combination with durvalumab is indicated for the first line treatment of adults with advanced or unresectable hepatocellular carcinoma (hcc). imjudo in combination with durvalumab and platinum-based chemotherapy is indicated for the first-line treatment of adults with metastatic non-small cell lung cancer (nsclc) with no sensitising egfr mutations or alk positive mutations.